236 related articles for article (PubMed ID: 9303354)
1. Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.
Kanzawa F; Nishio K; Ishida T; Fukuda M; Kurokawa H; Fukumoto H; Nomoto Y; Fukuoka K; Bojanowski K; Saijo N
Br J Cancer; 1997; 76(5):571-81. PubMed ID: 9303354
[TBL] [Abstract][Full Text] [Related]
2. Structural considerations of NK109, an antitumor benzo[c]phenanthridine alkaloid.
Nakanishi T; Suzuki M; Saimoto A; Kabasawa T
J Nat Prod; 1999 Jun; 62(6):864-7. PubMed ID: 10395504
[TBL] [Abstract][Full Text] [Related]
3. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
[TBL] [Abstract][Full Text] [Related]
4. Substituted benzo[i]phenanthridines as mammalian topoisomerase-targeting agents.
Makhey D; Li D; Zhao B; Sim SP; Li TK; Liu A; Liu LF; LaVoie EJ
Bioorg Med Chem; 2003 Apr; 11(8):1809-20. PubMed ID: 12659767
[TBL] [Abstract][Full Text] [Related]
5. Identification of a drug target motif: an anti-tumor drug NK109 interacts with a PNxxxxP.
Morohashi K; Yoshino A; Yoshimori A; Saito S; Tanuma S; Sakaguchi K; Sugawara F
Biochem Pharmacol; 2005 Jul; 70(1):37-46. PubMed ID: 15899472
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of derivatives of NK109, 7-OH benzo[c]phenanthridine alkaloid, and evaluation of their cytotoxicities and reduction-resistant properties.
Nakanishi T; Masuda A; Suwa M; Akiyama Y; Hoshino-Abe N; Suzuki M
Bioorg Med Chem Lett; 2000 Oct; 10(20):2321-3. PubMed ID: 11055347
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
8. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
Hasegawa S; Abe T; Naito S; Kotoh S; Kumazawa J; Hipfner DR; Deeley RG; Cole SP; Kuwano M
Br J Cancer; 1995 May; 71(5):907-13. PubMed ID: 7734314
[TBL] [Abstract][Full Text] [Related]
9. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.
Kasahara K; Fujiwara Y; Sugimoto Y; Nishio K; Tamura T; Matsuda T; Saijo N
J Natl Cancer Inst; 1992 Jan; 84(2):113-8. PubMed ID: 1310509
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative activity of O4-benzo[c]phenanthridine alkaloids against HCT-116 and HL-60 tumor cells.
Hatae N; Fujita E; Shigenobu S; Shimoyama S; Ishihara Y; Kurata Y; Choshi T; Nishiyama T; Okada C; Hibino S
Bioorg Med Chem Lett; 2015 Jul; 25(14):2749-52. PubMed ID: 26026362
[TBL] [Abstract][Full Text] [Related]
11. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.
Asano T; Zwelling LA; An T; McWatters A; Herzog CE; Mayes J; Loughlin SM; Kleinerman ES
Br J Cancer; 1996 Jun; 73(11):1373-80. PubMed ID: 8645582
[TBL] [Abstract][Full Text] [Related]
12. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
[TBL] [Abstract][Full Text] [Related]
13. A topoisomerase II inhibitor, NK109, induces DNA single- and double-strand breaks and apoptosis.
Fukuda M; Inomata M; Nishio K; Fukuoka K; Kanzawa F; Arioka H; Ishida T; Fukumoto H; Kurokawa H; Oka M; Saijo N
Jpn J Cancer Res; 1996 Oct; 87(10):1086-91. PubMed ID: 8957068
[TBL] [Abstract][Full Text] [Related]
14. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC
Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558
[TBL] [Abstract][Full Text] [Related]
15. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Naito S; Hasegawa S; Yokomizo A; Koga H; Kotoh S; Kuwano M; Kumazawa J
Jpn J Cancer Res; 1995 Nov; 86(11):1112-8. PubMed ID: 8567404
[TBL] [Abstract][Full Text] [Related]
16. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
Hill BT; Whelan RD; Shellard SA; McClean S; Hosking LK
Invest New Drugs; 1994; 12(3):169-82. PubMed ID: 7896535
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.
Jensen PB; Roed H; Sehested M; Demant EJ; Vindeløv L; Christensen IJ; Hansen HH
Cancer Chemother Pharmacol; 1992; 31(1):46-52. PubMed ID: 1360876
[TBL] [Abstract][Full Text] [Related]
18. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype.
Kamath N; Grabowski D; Ford J; Ganapathi R
Br J Cancer; 1993 Jun; 67(6):1203-8. PubMed ID: 8099806
[TBL] [Abstract][Full Text] [Related]
19. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of multiple drug resistance in human bladder cancer cell lines.
Shinohara N; Liebert M; Wedemeyer G; Chang JH; Grossman HB
J Urol; 1993 Aug; 150(2 Pt 1):505-9. PubMed ID: 8100862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
